Search News Archives
Special Offers and Promotions
Conferences | Events
Neurodegeneration Research Benefits from Protein Delivery Reagent
AMSBIO announces that Belgian researchers** have cited use of BioPORTER Protein Delivery Reagent to introduce Tau seeds into HEK293 cells.
BioPORTER Protein Delivery Reagent is a unique lipid formulation that allows direct translocation of proteins into living cells.
Neurodegenerative tauopathies, including Alzheimer disease and frontotemporal dementias, are characterized by neurofibrillary tangles (NFT) composed of intracellular hyperphosphorylated Tau aggregates. Predominantly expressed in neurons, Tau is a microtubule (MT)-binding protein that stabilizes and promotes the assembly of MTs, and the Tau-MT interactions are negatively regulated by phosphorylation of Tau. A naturally unfolded soluble protein under normal conditions, Tau acquires highly ordered ß-pleated sheet structures as it assembles into insoluble hyperphosphorylated paired helical filaments as well as less frequent straight filaments that constitute NFTs in Alzheimer disease and related tauopathies. Significant correlation of total NFT burden with cognitive decline has been observed in Alzheimer disease patients.
In the Belgian research prion-like seeding and propagation of Tau-pathology was demonstrated experimentally and may underlie the stereotyped progression of neurodegenerative Tauopathies. The researchers analyzed the repercussions of prion-like spreading of Tau-pathology via neuronal connections on neuronal network function in TauP301S transgenic mice.
BioPORTER® Protein Delivery Reagent provided the researchers with a quick and easy method to study protein function without the need for cloning and DNA transfection. The BioPORTER® reagent lipid captures proteins and transports them inside the target cells. The delivered proteins retain their structure and function while leaving the transduced cells unharmed. The BioPORTER® Reagent is especially useful when studying protein function in cells that are difficult to transfect using traditional DNA transfection reagents.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.